533 related articles for article (PubMed ID: 30606884)
21. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
22. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
Bayraktar S; Hernadez-Aya LF; Lei X; Meric-Bernstam F; Litton JK; Hsu L; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(5):1202-11. PubMed ID: 21800293
[TBL] [Abstract][Full Text] [Related]
23. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
Bayraktar UD; Chen E; Bayraktar S; Sands LR; Marchetti F; Montero AJ; Rocha-Lima CM
Cancer; 2011 Jun; 117(11):2364-70. PubMed ID: 24048783
[TBL] [Abstract][Full Text] [Related]
24. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
[TBL] [Abstract][Full Text] [Related]
25. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois C; Shi Q; Meyers JP; Iveson T; Alberts SR; de Gramont A; Sobrero AF; Haller DG; Oki E; Shields AF; Goldberg RM; Kerr R; Lonardi S; Yothers G; Kelly C; Boukovinas I; Labianca R; Sinicrope FA; Souglakos I; Yoshino T; Meyerhardt JA; André T; Papamichael D; Taieb J
J Clin Oncol; 2023 Feb; 41(4):803-815. PubMed ID: 36306483
[TBL] [Abstract][Full Text] [Related]
29. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
[TBL] [Abstract][Full Text] [Related]
30. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
Ng K; Ogino S; Meyerhardt JA; Chan JA; Chan AT; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Benson AB; Schaefer PL; Whittom R; Hantel A; Goldberg RM; Bertagnolli MM; Venook AP; Fuchs CS
J Natl Cancer Inst; 2011 Oct; 103(20):1540-51. PubMed ID: 21849660
[TBL] [Abstract][Full Text] [Related]
31. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
Fontana E; Meyers J; Sobrero A; Iveson T; Shields AF; Taieb J; Yoshino T; Souglakos I; Smyth EC; Lordick F; Moehler M; Giraut A; Harkin A; Labianca R; Meyerhardt J; André T; Boukovinas I; Lonardi S; Saunders M; Vernerey D; Oki E; Georgoulias V; Ben-Aharon I; Shi Q
J Clin Oncol; 2021 Dec; 39(36):4009-4019. PubMed ID: 34752136
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
[TBL] [Abstract][Full Text] [Related]
33. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
34. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Cohen R; Taieb J; Fiskum J; Yothers G; Goldberg R; Yoshino T; Alberts S; Allegra C; de Gramont A; Seitz JF; O'Connell M; Haller D; Wolmark N; Erlichman C; Zaniboni A; Lonardi S; Kerr R; Grothey A; Sinicrope FA; André T; Shi Q
J Clin Oncol; 2021 Feb; 39(6):642-651. PubMed ID: 33356421
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
[TBL] [Abstract][Full Text] [Related]
36. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
[TBL] [Abstract][Full Text] [Related]
37. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
Atci MM; Akagunduz B; Demir M; Arikan R; Ay S; Ozer M; Ayhan M; Cil I; Demir N; Ozyurt N; Karakaya G; Cevik GT; Onder AH; Selvi O; Sakin A
J Chemother; 2023 Feb; 35(1):19-28. PubMed ID: 35174772
[TBL] [Abstract][Full Text] [Related]
38. Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice.
Satkunam N; Wei X; Biagi JJ; Nanji S; Booth CM
J Natl Compr Canc Netw; 2016 Dec; 14(12):1548-1554. PubMed ID: 27956539
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.
Basile D; Rosati G; Bergamo F; Garattini SK; Banzi M; Zampino M; Bozzarelli S; Marchetti P; Galli F; Galli F; Longarini R; Zaniboni A; Ferrari D; De Placido S; Frassineti LG; Nicolini M; Cinieri S; Priscindiaro M; Ziranu P; Caccialanza R; Pastorino A; Mosconi S; Aprile G
Clin Colorectal Cancer; 2023 Jun; 22(2):190-198. PubMed ID: 36935327
[TBL] [Abstract][Full Text] [Related]
40. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.
Oppong BA; Pharmer LA; Oskar S; Eaton A; Stempel M; Patil S; King TA
Cancer Med; 2014 Aug; 3(4):1025-34. PubMed ID: 24944108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]